Special Issue "Acute Myeloid Leukemia"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 September 2019).
Interests: AML; HSCT; MRD; novel agents; Guidelines; ELN; genetics; cytogenetics; MDS; chemotherapy
Notwithstanding crucial advances in the understanding of blood cancers’ biology and pathogenesis, the standard therapeutic approach to acute myeloid leukemia (AML) has not changed meaningfully in the last four decades. However, although the “7+3”-based regimen remains the backbone of upfront AML treatment in fit patients, the recent approval of several promising drugs has paved the way for the opportunity of delivering targeted treatments to patients with specific molecular subtypes. Actually, several clinical trials demonstrated that these targeted molecules, as single agents or in combination with high- or low-dose chemotherapy, are well tolerated while maintaining or increasing their efficacy in terms of overall and event-free survival. The role of these new agents, alone or in association with low-dose chemotherapy, appears particularly promising in special categories such as those of older patients not eligible for intensive approaches and the elderly. Finally, some of the new agents are currently under investigation as maintenance drugs in the post-bone marrow transplant setting, as an attempt to improve post-transplant outcomes and reduce the rates of relapse. This application sounds particularly attractive to capture situations of pre-transplant persistence of “measurable residual disease”. In the present Special Issue, we review how these new therapies are expected to change the therapeutic landscape of AML, as a step towards the right direction to deal with a group of “very-difficult-to-treat” diseases.
Dr. Adriano Venditti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.